Chancery Urged To Deny Alexion's Bid To Revisit Fee Ruling
Former shareholders of a biopharmaceutical business that Alexion Pharmaceuticals Inc. acquired are asking the Delaware Chancery Court to deny Alexion's bid for the court to reconsider a ruling that shifted fees...To view the full article, register now.
Already a subscriber? Click here to view full article